Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Price, News & Analysis

Frequency Therapeutics logo

About Frequency Therapeutics Stock (NASDAQ:FREQ)

Key Stats

Today's Range
$0.28
$0.32
50-Day Range
$0.22
$14.98
52-Week Range
$0.18
$16.00
Volume
309,164 shs
Average Volume
822,537 shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FREQ Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Percheron Therapeutics Advances with Strong Funding and Trials
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
See More Headlines

FREQ Stock Analysis - Frequently Asked Questions

Frequency Therapeutics, Inc. (NASDAQ:FREQ) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.16.

Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Mizuho Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Frequency Therapeutics investors own include Tesla (TSLA), ImmunoGen (IMGN), Advanced Micro Devices (AMD), AMC Entertainment (AMC), Ovintiv (OVV), Plug Power (PLUG) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/15/2021
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FREQ
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

Net Income
$-81,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.07 million
Book Value
$1.96 per share

Miscellaneous

Free Float
30,385,000
Market Cap
$10.94 million
Optionable
Not Optionable
Beta
0.84
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FREQ) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners